Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
Shattuck Labs Reports Preclinical Data Demonstrating Therapeutic Utility Of TRIM7 Inhibition To Prevent Or Reverse Acquired Resistance To Immune Checkpoint Therapy
Shattuck Labs 報告的臨床前數據表明 TRIM7 抑制劑在預防或逆轉對免疫檢查點療法的獲得性耐藥方面的治療效用
These data were featured in an oral presentation during the AACR Annual Meeting 2024, being held from April 5-10, 2024, in San Diego, California.
這些數據在2024年4月5日至10日在加利福尼亞州聖地亞哥舉行的2024年AACR年會期間的口頭陳述中進行了介紹。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。